Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLTE NASDAQ:COGT NASDAQ:IMCR NASDAQ:MIRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$138.16+1.0%$154.12$56.10▼$200.00$5.49B-1.24235,207 shs154,909 shsCOGTCogent Biosciences$33.10+1.5%$34.62$6.88▼$43.73$5.57B0.342.31 million shs1.48 million shsIMCRImmunocore$28.96+1.2%$29.61$27.56▼$40.71$1.46B0.74424,346 shs276,831 shsMIRMMirum Pharmaceuticals$99.35-0.2%$97.79$47.89▼$114.99$6.07B0.5734,841 shs553,578 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+0.17%-5.27%-12.02%-16.61%+123.98%COGTCogent Biosciences+3.95%-0.52%-5.53%-4.06%+349.31%IMCRImmunocore+2.58%-0.49%-2.32%-7.26%-19.52%MIRMMirum Pharmaceuticals+5.89%+7.62%-6.87%+9.79%+105.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$138.16+1.0%$154.12$56.10▼$200.00$5.49B-1.24235,207 shs154,909 shsCOGTCogent Biosciences$33.10+1.5%$34.62$6.88▼$43.73$5.57B0.342.31 million shs1.48 million shsIMCRImmunocore$28.96+1.2%$29.61$27.56▼$40.71$1.46B0.74424,346 shs276,831 shsMIRMMirum Pharmaceuticals$99.35-0.2%$97.79$47.89▼$114.99$6.07B0.5734,841 shs553,578 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+0.17%-5.27%-12.02%-16.61%+123.98%COGTCogent Biosciences+3.95%-0.52%-5.53%-4.06%+349.31%IMCRImmunocore+2.58%-0.49%-2.32%-7.26%-19.52%MIRMMirum Pharmaceuticals+5.89%+7.62%-6.87%+9.79%+105.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLTEBelite Bio 2.63Moderate Buy$203.0046.93% UpsideCOGTCogent Biosciences 2.86Moderate Buy$43.7332.11% UpsideIMCRImmunocore 2.56Moderate Buy$56.7195.84% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$138.3639.26% UpsideCurrent Analyst Ratings BreakdownLatest IMCR, MIRM, BLTE, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026MIRMMirum Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$140.00 ➝ $150.006/8/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)6/2/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform ➝ Buy$145.006/1/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/29/2026COGTCogent Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.005/26/2026BLTEBelite Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$223.00 ➝ $215.005/22/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/22/2026BLTEBelite Bio Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$217.005/22/2026BLTEBelite Bio BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026BLTEBelite Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$200.005/19/2026MIRMMirum Pharmaceuticals Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$145.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLTEBelite BioN/AN/AN/AN/A$20.54 per shareN/ACOGTCogent BiosciencesN/AN/AN/AN/A$3.84 per shareN/AIMCRImmunocore$400.02M3.68N/AN/A$7.52 per share3.85MIRMMirum Pharmaceuticals$521.31M11.62$0.05 per share1,952.56$6.12 per share16.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLTEBelite Bio-$77.61M-$2.53N/A114.18N/AN/A-13.14%-12.88%8/10/2026 (Estimated)COGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)IMCRImmunocore-$35.51M-$0.55N/A33.29N/A-6.68%-7.07%-2.55%8/6/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$13.61N/A431.96N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)Latest IMCR, MIRM, BLTE, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BLTEBelite Bio-$0.60-$0.34+$0.26-$0.68N/AN/A5/6/2026Q1 2026IMCRImmunocore-$0.26$0.25+$0.51$0.25$145.20 million$106.68 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLTEBelite BioN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLTEBelite BioN/A33.7133.71COGTCogent Biosciences0.4115.1415.14IMCRImmunocore1.004.184.15MIRMMirum Pharmaceuticals1.282.091.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLTEBelite Bio0.53%COGTCogent BiosciencesN/AIMCRImmunocore84.50%MIRMMirum PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipBLTEBelite Bio13.29%COGTCogent Biosciences6.59%IMCRImmunocore10.10%MIRMMirum Pharmaceuticals8.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLTEBelite Bio1040.08 million34.76 millionNot OptionableCOGTCogent Biosciences80170.87 million159.61 millionOptionableIMCRImmunocore32050.87 million45.58 millionOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionableIMCR, MIRM, BLTE, and COGT HeadlinesRecent News About These CompaniesMirum Pharmaceuticals (NASDAQ:MIRM) Given New $150.00 Price Target at Morgan StanleyJune 11 at 8:46 AM | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells $469,100.00 in StockJune 10 at 5:54 AM | insidertrades.comInsider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 5,000 Shares of StockJune 9 at 11:13 PM | marketbeat.comCenterBook Partners LP Purchases 37,010 Shares of Mirum Pharmaceuticals, Inc. $MIRMJune 9 at 3:59 AM | marketbeat.comMirum Pharmaceuticals, Inc. $MIRM Shares Sold by Clearbridge Investments LLCJune 9 at 3:51 AM | marketbeat.comGeode Capital Management LLC Has $83.98 Million Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRMJune 8, 2026 | marketbeat.comWhy Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?June 5, 2026 | zacks.comMirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL CongressJune 4, 2026 | finance.yahoo.comMirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026June 4, 2026 | businesswire.comChristopher Peetz Sells 30,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) StockJune 3, 2026 | insidertrades.com47,630 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by Hillsdale Investment Management Inc.June 1, 2026 | marketbeat.comMirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026May 30, 2026 | businesswire.comFisher Asset Management LLC Makes New $1.11 Million Investment in Mirum Pharmaceuticals, Inc. $MIRMMay 30, 2026 | marketbeat.comSBI Okasan Asset Management Co.Ltd. Buys Shares of 16,000 Mirum Pharmaceuticals, Inc. $MIRMMay 29, 2026 | marketbeat.comMirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline AdvanceMay 27, 2026 | marketbeat.comPenn Capital Management Company LLC Has $22.32 Million Position in Mirum Pharmaceuticals, Inc. $MIRMMay 27, 2026 | marketbeat.comWilliam Blair Investment Management LLC Buys 23,442 Shares of Mirum Pharmaceuticals, Inc. $MIRMMay 26, 2026 | marketbeat.comMirum’s US$600 Million Zero-Coupon Convertible Note Issue Might Change The Case For Investing In Mirum Pharmaceuticals (MIRM)May 25, 2026 | finance.yahoo.com41,857 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by Thrivent Financial for LutheransMay 24, 2026 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of "Buy" from BrokeragesMay 24, 2026 | marketbeat.comMirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026May 21, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026IMCR, MIRM, BLTE, and COGT Company DescriptionsBelite Bio NASDAQ:BLTE$138.16 +1.31 (+0.96%) Closing price 04:00 PM EasternExtended Trading$138.10 -0.06 (-0.04%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Cogent Biosciences NASDAQ:COGT$33.10 +0.48 (+1.47%) Closing price 04:00 PM EasternExtended Trading$33.50 +0.40 (+1.21%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Immunocore NASDAQ:IMCR$28.96 +0.34 (+1.19%) Closing price 04:00 PM EasternExtended Trading$28.95 -0.01 (-0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Mirum Pharmaceuticals NASDAQ:MIRM$99.35 -0.19 (-0.19%) Closing price 04:00 PM EasternExtended Trading$99.37 +0.02 (+0.02%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
